Context Therapeutics Inc 8-K, filed Jun 14, 2024
Context Therapeutics Inc. (CNTX)
8-K
2024-06-14
For: 2024-06-13
View Original
Added on
April 10, 2026
About this 8-K
Context Therapeutics Inc filed this 8-K on June 14, 2024, reporting on events of June 13, 2024.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
_______________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2024
_______________________
(Exact name of registrant as specified in its charter)
_______________________
| (State of other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Title of each class | Trading | Name of exchange | |||||||||||||||
| Symbol | on which registered | ||||||||||||||||
$0.001 par value per share | |||||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 13, 2024, Context Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders. As of April 15, 2024, the record date for the Annual Meeting, there were 15,966,053 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 8,486,458, or 53.15%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held and cumulative voting for directors is not permitted. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting.
Proposal 1. Ratification of Appointment of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024. The voting on this proposal is set forth below:
| For | Against | Abstentions | Broker Non-Votes | |||||||||||||||||||||||
| Ratification of CohnReznick LLP | 8,364,879 | 117,835 | 3,744 | --- | ||||||||||||||||||||||
Proposal 2. Election of Directors
The Company’s stockholders elected the following director nominees to the Company’s Board of Directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.
| For | Withheld | Broker Non-Votes | ||||||||||||||||||
| Richard Berman | 4,774,152 | 1,873,694 | 1,838,612 | |||||||||||||||||
| Dr. Philip Kantoff | 6,047,097 | 600,749 | 1,838,612 | |||||||||||||||||
| Martin Lehr | 6,637,406 | 10,440 | 1,838,612 | |||||||||||||||||
| Jennifer Evans Stacey | 5,028,962 | 1,618,884 | 1,838,612 | |||||||||||||||||
| Linda West | 6,063,962 | 583,884 | 1,838,612 | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 14, 2024 | Context Therapeutics Inc. | ||||
By: /s/ Martin A. Lehr | |||||
| Name: Martin A. Lehr | |||||
| Title: Chief Executive Officer | |||||